Nonvalvular atrial fibrillation (often shortened to NVAF) is atrial fibrillation that occurs without certain specific heart valve problems, particularly moderate-to-severe mitral stenosis from rheumatic heart disease or a mechanical heart valve. The distinction matters primarily because it determines which type of blood thinner you can safely take to prevent stroke. Of the estimated 52.5 million people worldwide living with atrial fibrillation, the vast majority have the nonvalvular form.
Why the “Nonvalvular” Label Exists
Atrial fibrillation itself is the same condition regardless of the label: the upper chambers of your heart quiver chaotically instead of beating in a steady rhythm. The “nonvalvular” distinction was created to guide decisions about blood-thinning medications, not to describe a different type of irregular heartbeat.
Newer oral blood thinners (called DOACs) were tested in large trials that excluded people with moderate-to-severe rheumatic mitral stenosis and mechanical heart valves. Those two conditions change how blood clots form in the heart, and the newer drugs haven’t been proven safe or effective for them. Everyone else with atrial fibrillation, including people with other valve problems like aortic stenosis, mild mitral regurgitation, or a biological valve replacement, falls into the “nonvalvular” category and can be considered for these newer medications.
The terminology is actually being phased out. Both the American Heart Association (in 2019) and the European Society of Cardiology (in 2016) recommended dropping the “nonvalvular” label entirely because it caused confusion. Instead, guidelines now simply specify that people with mechanical heart valves or moderate-to-severe rheumatic mitral stenosis should not use DOACs. Everyone else is eligible. You may still encounter the term in older medical records or from providers who use it out of habit.
How It Differs From Valvular Afib
The practical difference comes down to two conditions. Valvular atrial fibrillation means you have Afib alongside either a mechanical heart valve (the metal kind that clicks) or mitral stenosis caused by rheumatic fever, where the valve between your left upper and lower heart chambers has stiffened and narrowed. These conditions create a low-flow state in the left side of the heart that significantly raises the risk of blood clots forming, and they require warfarin specifically for clot prevention.
Other valve problems, prosthetic valves in non-mitral positions, and a history of mitral valve repair do not place you in the valvular category. Research has not consistently linked those conditions to the same elevated clot risk that rheumatic mitral stenosis and mechanical valves carry.
Symptoms and Diagnosis
Nonvalvular Afib feels the same as any other atrial fibrillation. Common symptoms include palpitations (a fluttering, pounding, or racing sensation in your chest), extreme fatigue, dizziness, shortness of breath, and occasionally chest pain or fainting. Some people have no symptoms at all and discover their Afib incidentally during a routine checkup or when wearing a smartwatch that flags an irregular rhythm.
Diagnosis requires an electrocardiogram (ECG), which records the electrical activity of your heart as a graph. In Afib, the ECG shows a fast, chaotic pattern with no organized rhythm in the upper chambers. Once Afib is confirmed, your doctor determines whether it’s “nonvalvular” by evaluating your heart valves, typically with an echocardiogram (an ultrasound of the heart).
Common Causes and Risk Factors
The most common driver of nonvalvular Afib is high blood pressure, which over time damages and stiffens the heart’s upper chambers. Coronary heart disease is the other leading cause. Age is a major risk factor: your likelihood rises significantly after 65.
A long list of other conditions can contribute, including diabetes, heart failure, obesity, sleep apnea, chronic kidney disease, COPD, and an overactive thyroid. Lifestyle factors play a significant role too. Heavy alcohol use, especially binge drinking, raises your risk, and even moderate amounts can trigger episodes in some people. Smoking increases risk in proportion to how long you’ve smoked, though quitting helps. Emotional stress and panic disorders have also been linked to higher rates of Afib.
Interestingly, intense endurance exercise can increase risk, particularly in competitive athletes and men, while moderate physical activity has a protective effect. Cocaine and amphetamines can trigger Afib directly.
Stroke Risk and How It’s Measured
The biggest danger of Afib is stroke. When the upper chambers quiver instead of contracting properly, blood can pool and form clots. If a clot travels to the brain, it causes a stroke. Doctors use a scoring system called CHA₂DS₂-VASc to estimate your personal stroke risk. Each letter represents a risk factor that adds points:
- Congestive heart failure: 1 point
- Hypertension: 1 point
- Age 75 or older: 2 points
- Diabetes: 1 point
- Prior stroke or clot: 2 points
- Vascular disease (prior heart attack, peripheral artery disease): 1 point
- Age 65 to 74: 1 point
- Female sex: 1 point
A score of 0 for men or 1 for women means your stroke risk is low enough that blood thinners generally aren’t recommended. Higher scores mean greater risk and a stronger case for anticoagulation. In the original study behind this scoring system, patients in those lowest-risk groups had zero blood clot events.
Blood Thinners for NVAF
For most people with nonvalvular Afib and an elevated stroke risk score, newer oral blood thinners (DOACs) are preferred over the older drug warfarin. The reasons are practical: DOACs have a more predictable effect in the body, don’t require regular blood draws to monitor levels, and have fewer food and drug interactions.
In pooled analyses, DOACs reduced the combined risk of stroke and systemic blood clots by about 24% compared to warfarin. They also cut the risk of bleeding inside the skull by more than half. Major bleeding overall was similar between the two. These advantages hold even in NVAF patients who have other (non-disqualifying) valve conditions.
Warfarin remains the only option for people with mechanical heart valves or moderate-to-severe rheumatic mitral stenosis, which is precisely why the valvular/nonvalvular distinction was created in the first place.
Beyond Blood Thinners: Rhythm Control
Preventing stroke is one priority. The other is managing the irregular rhythm itself. The 2023 joint guidelines from major cardiology organizations emphasize early rhythm control, meaning actively working to restore and maintain a normal heart rhythm rather than simply controlling how fast the heart beats during Afib episodes.
For selected patients, catheter ablation (a procedure that destroys tiny areas of heart tissue causing the erratic signals) now carries a top-level recommendation as a first-line treatment, not just a backup when medications fail. This is a significant shift from earlier guidelines. The upgrade was based on trials showing ablation outperformed drug therapy for maintaining normal rhythm, particularly in patients with heart failure and reduced pumping function.
Alongside rhythm management, guidelines stress ongoing optimization of modifiable risk factors: controlling blood pressure, managing weight, treating sleep apnea, limiting alcohol, and staying physically active at a moderate level.
When Blood Thinners Aren’t an Option
Some people with NVAF face situations where blood thinners carry too high a bleeding risk, such as a history of serious bleeding in the brain, gut, or lungs, severe kidney or liver disease, certain cancers, or coagulation disorders. For these patients, a small device can be implanted to physically seal off the left atrial appendage, a small pouch in the heart where most Afib-related clots form.
These devices (the most widely known is the Watchman) are delivered through a catheter, typically via a vein in the leg. Guidelines give this approach a moderately strong recommendation for NVAF patients with high stroke risk who have long-term contraindications to blood thinners. The 2023 guidelines upgraded this recommendation based on accumulating safety and effectiveness data.